Evidence map›Paper›PMID 37031161›Full record

ArticleAdvanced healthcare materials2023

Engineered Curli Nanofilaments as a Self-Adjuvanted Antigen Delivery Platform.

Félix Lamontagne, Dominic Arpin, Mélanie Côté-Cyr, Vinay Khatri, Philippe St-Louis, Laurie Gauthier, Denis Archambault, Steve Bourgault

Open access · hybridAbstract read
In one paragraph

Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Félix LamontagneDepartment of Chemistry, Université du Québec à Montréal, C.P.8888, Succursale Centre-Ville, Montreal, H3C 3P8, Canada.
Dominic ArpinDepartment of Chemistry, Université du Québec à Montréal, C.P.8888, Succursale Centre-Ville, Montreal, H3C 3P8, Canada.
Mélanie Côté-CyrDepartment of Chemistry, Université du Québec à Montréal, C.P.8888, Succursale Centre-Ville, Montreal, H3C 3P8, Canada.
Vinay KhatriDepartment of Chemistry, Université du Québec à Montréal, C.P.8888, Succursale Centre-Ville, Montreal, H3C 3P8, Canada.
Philippe St-LouisThe Swine and Poultry Infectious Diseases Research Centre (CRIPA), Saint-Hyacinthe, J2S 2M2, Canada.
Laurie GauthierThe Swine and Poultry Infectious Diseases Research Centre (CRIPA), Saint-Hyacinthe, J2S 2M2, Canada.
Denis ArchambaultThe Swine and Poultry Infectious Diseases Research Centre (CRIPA), Saint-Hyacinthe, J2S 2M2, Canada.
Steve BourgaultDepartment of Chemistry, Université du Québec à Montréal, C.P.8888, Succursale Centre-Ville, Montreal, H3C 3P8, Canada.ORCID 0000-0002-5563-8787
Université du Québec à Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteinaceous nanoparticles constitute efficient antigen delivery systems in vaccine formulations due to their size and repetitive nature that mimic most invading pathogens and promote immune activation. Nonetheless, the coadministration of an adjuvant with subunit nanovaccines is usually required to induce a robust, long-lasting, and protective immune response. Herein, the protein Curli-specific gene A (CsgA), which is known to self-assemble into nanofilaments contributing to bacterial biofilm, is exploited to engineer an intrinsically immunostimulatory antigen delivery platform. Three repeats of the M2e antigenic sequence from the influenza A virus matrix 2 protein are merged to the N-terminal domain of engineered CsgA proteins. These chimeric 3M2e-CsgA spontaneously self-assemble into antigen-displaying cross-β-sheet nanofilaments that activate the heterodimeric toll-like receptors 2 and 1. The resulting nanofilaments are avidly internalized by antigen-presenting cells and stimulate the maturation of dendritic cells. Without the need of any additional adjuvants, both assemblies show robust humoral and cellular immune responses, which translate into complete protection against a lethal experimental infection with the H1N1 influenza virus. Notably, these CsgA-based nanovaccines induce neither overt systemic inflammation, nor reactogenicity, upon mice inoculation. These results highlight the potential of engineered CsgA nanostructures as self-adjuvanted, safe, and versatile antigen delivery systems to fight infectious diseases.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesAdjuvants, ImmunologicAnimalsAntibodies, ViralAutoantigensHumansMiceMice, Inbred BALB CViral Matrix ProteinsAdjuvants, ImmunologicAntibodies, ViralAutoantigensInfluenza VaccinesViral Matrix Proteinsantigen delivery platformscurli-specific gene Aimmunostimulantsinfluenza A virusnanofilamentsnanovaccines

Identifiers

PMID37031161
PMCPMC11468023
OpenAlexW4362722926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.